systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-328Research ArticleКАРДИОЛОГИЯCARDIOLOGYОсобенности лечения артериальной гипертонии у женщин в перименопаузеHypertension treatment features in perimenopausal womenЖернаковаЮ. В.ZhernakovaYu. V.uli001@mail.ruЧазоваИ. Е.ChazovaI. E.c34h@yandex.ruИнститут клинической кардиологии им. А.Л.Мясникова ФГБУ РКНПК Минздрава России, МоскваRussian Federation201423122022111510Copyright © Жернакова Ю.В., Чазова И.Е., 20222022Жернакова Ю.В., Чазова И.Е.Zhernakova Y.V., Chazova I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/328

Важнейшими причинами инвалидности у женщин являются хроническая сердечная недостаточность, развившаяся на фоне артериальной гипертонии (АГ), и мозговой инсульт. Вместе с тем распространенность АГ среди женщин в постменопаузе значительно выше, чем среди мужчин. У женщин АГ чаще развивается на фоне метаболических нарушений, в частности метаболического синдрома. В связи с этим препаратами выбора для лечения АГ у женщин в перименопаузе являются ингибиторы ангиотензинпревращающего фермента и блокаторы рецепторов ангиотензина. При необходимости комбинированной антигипертензивной терапии препаратами выбора могут служить агонисты имидазолиновых рецепторов, в частности моксонидин. Применение моксонидина у этой категории пациенток оправдано особенностями фармакологического действия препарата (снижение симпатической гиперактивации), высокой антигипертензивной эффективностью, а также дополнительными позитивными эффектами в отношении массы тела и основных метаболических показателей.

Major causes of disability among women are chronic heart failure, developed on arterial hypertension (AH) and cerebral stroke. However, the prevalence of AH among postmenopausal women is significantly higher than for men. Women are more likely to develop AH with metabolic disorders, including metabolic syndrome. Therefore, the drugs of choice to treat AH in women in perimenopauseare ACE inhibitors and Angiotensin II Receptor Blocker. If necessary, combination antihypertensive treatment drugs of choice are agonistsimidazoline receptors, such as moxonidine. The use of this category of patients havemoxonidine action justified by the features of the pharmacological action of this drug (decrease in sympathetic hyperactivity), high efficiency, antihypertensive as well as additional positive effects on body weight and metabolic parameters.

метаболический синдромартериальная гипертонияожирениемоксонидинменопаузаmetabolic syndromehypertensionobesitymoxonidine menopauseReferencesWHO. The World health statistics 2012 report: URL: http://who.int/ gho/publications/world_health_statistics/EN_WHS2012_Full.pdf (дата обращения: 22.02.2012).WHO. The World health statistics 2012 report: URL: http://who.int/ gho/publications/world_health_statistics/EN_WHS2012_Full.pdf (дата обращения: 22.02.2012).Peterson S, Peto V, Rayner M et al. European Cardiovascular Disease Statistics, 2nd edn. British Heart Foundation 2005.Peterson S, Peto V, Rayner M et al. European Cardiovascular Disease Statistics, 2nd edn. British Heart Foundation 2005.Pyorala K, Lehto S, De Bacquer D et al. EUROASPIRE I Group; EUROASPIRE II Group. Risk factor management in diabetic and non - diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 2004; 47: 1257-65.Pyorala K, Lehto S, De Bacquer D et al. EUROASPIRE I Group; EUROASPIRE II Group. Risk factor management in diabetic and non - diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 2004; 47: 1257-65.Guthrie J.R, Dennerstein L, Taffe J.R et al. The menopausal transition: a 9-year prospective population - based study. The Melbourne Women’s Midlife Health Project. Climacteric 2004; 7: 375-89.Guthrie J.R, Dennerstein L, Taffe J.R et al. The menopausal transition: a 9-year prospective population - based study. The Melbourne Women’s Midlife Health Project. Climacteric 2004; 7: 375-89.Pasquali R, Casimirri F, Venturoli S et al. Body fat distribution has weight - independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994; 43: 706-13.Pasquali R, Casimirri F, Venturoli S et al. Body fat distribution has weight - independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994; 43: 706-13.Piatti P.M, Monti L.D et al. Forearm insulin - and - non - insulin mediated glucose uptake and muscle metabolism in man: role of free fatty acids and blood glucose levels. Metab Clin Exp 1991; 40: 926-33.Piatti P.M, Monti L.D et al. Forearm insulin - and - non - insulin mediated glucose uptake and muscle metabolism in man: role of free fatty acids and blood glucose levels. Metab Clin Exp 1991; 40: 926-33.Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7.Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7.Rowe J.R, Young J.B, Minaker K.L et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-25.Rowe J.R, Young J.B, Minaker K.L et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-25.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; doi: 10.1093/eurheartj/eht151.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; doi: 10.1093/eurheartj/eht151.Rosen P, Ohhy P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructoseied rat. J Hypertens 1997; Suppl. 15: S31-S38.Rosen P, Ohhy P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructoseied rat. J Hypertens 1997; Suppl. 15: S31-S38.Ernsberger P. Pharmacology of moxonidine: and I1-imidazoline receptor agonist. J Cardiovasc Pharmacol 2000; 35 (7 Suppl. 4): S27-41.Ernsberger P. Pharmacology of moxonidine: and I1-imidazoline receptor agonist. J Cardiovasc Pharmacol 2000; 35 (7 Suppl. 4): S27-41.Chazova I, Schlaich M.P. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study. Intern J Hypertens 2013; 1-9; doi:10.1155/2013/541689Chazova I, Schlaich M.P. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study. Intern J Hypertens 2013; 1-9; doi:10.1155/2013/541689

The authors declare that there are no conflicts of interest present.